keyword
MENU ▼
Read by QxMD icon Read
search

Bendamustin

keyword
https://www.readbyqxmd.com/read/29651368/synchronous-pulmonary-neoplasms-a-chance-occurrence-or-is-there-more-than-meets-the-eye
#1
Uroosa Ibrahim, Amina Saqib, Manisha Pant, Gwenalyn Garcia, Marcel Odaimi
Primary bronchus-associated lymphoid tissue (BALT) lymphoma comprises 5% of non-Hodgkin's lymphoma (NHL) and usually has an indolent course. Synchronous primary lung cancers with BALT lymphoma are seldom seen in patients with adenocarcinoma of the lung. Synchronous squamous cell carcinoma (SCC) and BALT lymphoma is an extremely rare occurrence. We report an unusual case of stage 4 BALT lymphoma requiring treatment that revealed an underlying ipsilateral mass causing a diagnostic dilemma. An 84-year-old female with a history of systemic lupus erythematosus, deep vein thrombosis, and thrombotic microangiopathy presented to the hospital with cough and dyspnea on exertion...
February 6, 2018: Curēus
https://www.readbyqxmd.com/read/29623625/applying-a-multicriteria-decision-analysis-mcda-approach-to-elicit-stakeholders-preferences-in-italy-the-case-of-obinutuzumab-for-rituximab-refractory-indolent-non-hodgkin-lymphoma-inhl
#2
Martina Garau, Grace Hampson, Nancy Devlin, Nicola Amedeo Mazzanti, Antonio Profico
BACKGROUND: Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders' preferences and be explicit about the trade-offs that are being made. OBJECTIVE: The objective of this study was to use MCDA to obtain preferences and views on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to use these to assess the performance of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL)...
August 22, 2017: PharmacoEconomics open
https://www.readbyqxmd.com/read/29619501/bendamustine-plus-rituximab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-analysis
#3
Jung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, Won Seog Kim, Seok Jin Kim, Jae-Cheol Jo, Jin Seok Kim, Won-Sik Lee, Sung Yong Oh, Yong Park, Sung-Yong Kim, Mark Hong Lee, Ho Sup Lee, Young Rok Do
Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and mantle cell lymphoma. However, there were limited experiences of real-world practice of BR in diffuse large B cell lymphoma (DLBCL). In this study, we report the Korean experiences with BR in relapsed or refractory DLBCL who are not eligible for intensive chemotherapy and autologous stem cell transplantation. This is an observational, multicenter, retrospective analysis. Between December 2011 and December 2015, a total of 58 patients with relapsed or refractory DLBCL were treated with BR in 11 tertiary hospitals in Korea...
April 4, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29610969/bendamustine-and-rituximab-br-versus-dexamethasone-rituximab-and-cyclophosphamide-drc-in-patients-with-waldenstr%C3%A3-m-macroglobulinemia
#4
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, Stephen M Ansell, Shaji Kumar, Sikander Ailawadhi, Rebecca L King, Amber B Koehler, Craig B Reeder, Francis K Buadi, Angela Dispenzieri, Martha Q Lacy, David Dingli, Thomas E Witzig, Ronald S Go, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Nelson Leung, Thomas M Habermann, Suzanne Hayman, Yi Lin, Robert A Kyle, S Vincent Rajkumar, Morie A Gertz, Prashant Kapoor
The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients' MYD88L265P mutation status. Of 160 consecutive patients, 60 received BR (43 with relapsed/refractory WM) and 100 received DRC (50 had relapsed/refractory WM)...
April 3, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29603428/retrospective-analysis-of-front-line-treatment-efficacy-in-elderly-patients-with-diffuse-large-b-cell-lymphoma
#5
Chieh-Lung Cheng, Jia-Hau Liu, Sheng-Chieh Chou, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien
OBJECTIVES: To investigate the effectiveness of two chemotherapeutic regimens, bendamustine plus rituximab (BR) or reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (RD-RCHOP), in elderly patients with treatment-naïve diffuse large B-cell lymphoma. METHODS: A retrospective study was conducted to investigate the efficacy and safety of two frontline regimens, BR and RD-RCHOP in patients aged ≥ 75 years unfit for R-CHOP. RESULTS: From January 2011 to December 2015, 26 patients received BR and 34 RD-RCHOP...
March 30, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29602308/gold-nanoparticles-stabilize-peptide-drug-conjugates-for-sustained-targeted-drug-delivery-to-cancer-cells
#6
Kalishwaralal Kalimuthu, Bat-Chen Lubin, Andrii Bazylevich, Gary Gellerman, Ofer Shpilberg, Galia Luboshits, Michael A Firer
BACKGROUND: Peptide-drug-conjugates (PDCs) are being developed as an effective strategy to specifically deliver cytotoxic drugs to cancer cells. However one of the challenges to their successful application is the relatively low stability of peptides in the blood, liver and kidneys. Since AuNPs seem to have a longer plasma half-life than PDCs, one approach to overcoming this problem would be to conjugate the PDCs to gold nanoparticles (AuNPs), as these have demonstrated favorable physico-chemical and safety properties for drug delivery systems...
March 30, 2018: Journal of Nanobiotechnology
https://www.readbyqxmd.com/read/29594951/obinutuzumab-with-bendamustine-for-treating-follicular-lymphoma-refractory-to-rituximab-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#7
REVIEW
Rachid Rafia, Abdullah Pandor, Sarah Davis, John W Stevens, Sue Harnan, Mark Clowes, Youssef Sorour, Robert Cutting
As part of its single technology appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of obinutuzumab (Roche) to submit evidence on its clinical and cost effectiveness when used in combination with bendamustine in patients with follicular lymphoma (FL) refractory to rituximab. The Evidence Review Group (ERG), the School of Health and Related Research Technology Appraisal Group at the University of Sheffield, produced a document summarising the key points from the company submission alongside a critical review...
March 28, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29588545/validation-of-a-biological-score-to-predict-response-in-chronic-lymphocytic-leukemia-patients-treated-front-line-with-bendamustine-and-rituximab
#8
Massimo Gentile, Tait D Shanafelt, Gianluigi Reda, Francesca Romana Mauro, Katja Zirlik, Stefania Ciolli, Luca Laurenti, Maria Ilaria Del Principe, Davide Rossi, Nicola Di Renzo, Stefano Molica, Francesco Angrilli, Marta Coscia, Annalisa Chiarenza, Annamaria Giordano, Giovanna Cutrona, Kari G Chaffee, Sameer A Parikh, Giuseppina Uccello, Idanna Innocenti, Giovanni Tripepi, Graziella D'Arrigo, Ernesto Vigna, Anna Grazia Recchia, Yair Herishanu, Lev Shvidel, Tamar Tadmor, Agostino Cortelezzi, Giovanni Del Poeta, Gianluca Gaidano, Francesco Di Raimondo, Antonino Neri, Manlio Ferrarini, Robin Foà, Aaron Polliack, Fortunato Morabito
No abstract text is available yet for this article.
March 20, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29584548/overall-survival-benefit-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-who-received-obinutuzumab-plus-bendamustine-induction-and-obinutuzumab-maintenance-in-the-gadolin-study
#9
Bruce D Cheson, Neil Chua, Jiri Mayer, Greg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver Press, Gilles Salles, John G Gribben, Anne Lennard, Pieternella J Lugtenburg, Günter Fingerle-Rowson, Federico Mattiello, Andrea Knapp, Laurie H Sehn
Purpose To perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated with obinutuzumab (GA101; G) and bendamustine (B). Patients and Methods Patients with histologically documented, rituximab-refractory CD20+ indolent non-Hodgkin lymphoma received G 1,000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2 to 6) plus B 90 mg/m2 /d (days 1 and 2, all cycles) or B 120 mg/m2 /d monotherapy. Patients who did not experience disease progression with G-B received G maintenance (1,000 mg every 2 months) for up to 2 years...
March 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29572347/bendamustine-plus-rituximab-in-chronic-lymphocytic-leukemia-is-there-life-in-the-old-dog-yet
#10
EDITORIAL
Clemens-Martin Wendtner
No abstract text is available yet for this article.
April 2018: Haematologica
https://www.readbyqxmd.com/read/29562156/venetoclax-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia
#11
RANDOMIZED CONTROLLED TRIAL
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P Kater
BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. METHODS: In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group)...
March 22, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29537344/r-bendamustine-in-the-treatment-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#12
Roosa Enni Inkeri Prusila, Kirsi-Maria Haapasaari, Katja Marin, Marjukka Pollari, Ylermi Soini, Martine Vornanen, Marja-Liisa Karjalainen-Lindsberg, Taina Turpeenniemi-Hujanen, Outi Kuittinen
No abstract text is available yet for this article.
March 14, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29532919/impact-of-novel-therapies-for-mantle-cell-lymphoma-in-the-real-world-setting-a-report-from-the-uk-s-haematological-malignancy-research-network-hmrn
#13
Alexandra Smith, Eve Roman, Simon Appleton, Debra Howell, Rod Johnson, Cathy Burton, Russell Patmore
The treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether the effects observed in clinical trials have translated into the real-world setting. To investigate this, we examined first-line and relapsed/refractory (RR) disease management in 335 MCL patients diagnosed between 2004 and 2015 in an established population-based patient cohort, along with data on demographic, diagnostic and prognostic factors...
March 13, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29529009/quantification-of-idelalisib-in-human-plasma-by-ultra-performance-liquid-chromatography-coupled-to-mass-spectrometry-in-negative-ionization-mode
#14
Huu H Huynh, Clara Roessle, Hélène Sauvageon, Alain Plé, Isabelle Madelaine, Catherine Thieblemont, Samia Mourah, Lauriane Goldwirt
BACKGROUND: Idelalisib is the first orally active selective phosphatidylinositol 3-kinase delta inhibitor approved by Food and Drug Administration and European Medicines Agency in 2014 for the treatment of several types of blood cancer. Idelalisib is widely used as a monotherapy or in combination with rituximab, bendamustine, or ofatumumab with a significant efficacy. However, idelalisib has shown increased risk of infection and a higher frequency of serious adverse events. It may be useful to determine idelalisib concentration in human plasma to adjust dose and to manage adverse effects in clinical practice...
April 2018: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29500147/a-retrospective-study-of-double-hit-lymphomas-in-elderly-patients-aged-70-years-overall-outcomes
#15
Christie Hancock, Phillip Knouse, Imad Almanaseer, Jacob Bitran
BACKGROUND: Double-hit lymphomas (DHLs) are high-grade diffuse large B-cell lymphomas with concurrent translocations involving myc and bcl-2 and/or bcl-6. A patient with DHL often has advanced disease at presentation and typically responds poorly to standard therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). More intensive treatment regimens have been studied; however, few data are available on the outcomes in elderly patients (aged > 70 years) treated with these therapies...
April 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29486795/the-first-in-class-alkylating-deacetylase-inhibitor-molecule-tinostamustine-shows-antitumor-effects-and-is-synergistic-with-radiotherapy-in-preclinical-models-of-glioblastoma
#16
Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen, Thomas Mehrling
BACKGROUND: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of the still dismal prognosis, further improvements are desperately needed, especially in the patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors, in which the benefit of standard treatment is less. Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor (AK-DACi) molecule that fuses the DNA damaging effect of bendamustine with the fully functional pan-histone deacetylase (HDAC) inhibitor, vorinostat, in a completely new chemical entity...
February 27, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29473209/bendamustine-based-conditioning-prior-to-asct-results-of-a-french-multicenter-study-of-474-patients-from-lysa-centers
#17
Sylvain P Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, Frederic Peyrade, Marie-Virginie Larcher, Momar Diouf, Luc Mathieu Fornecker, Roch Houot, Thomas Gastinne, Carole Soussain, Sandra Malak, Richard Lemal, Caroline Delette, Ahmad Ibrahim, Anne-Claire Gac, E Reboursière, Jean-Pierre Vilque, Mohamed Amine Bekadja, Rene-Olivier Casasnovas, Remy Gressin, Stéphanie Guidez, Diane Coso, Charles Herbaux, Krimo Bouabdallah, Eric Durot, Gandhi Damaj
Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine-based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B-cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m2 /day (50-250) on days -7 and -6...
February 23, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29468652/response-and-survival-for-primary-therapy-combination-regimens-and-maintenance-rituximab-in-waldenstr%C3%A3-m-macroglobulinaemia
#18
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, Toni E Dubeau, Patricia Severns, Lian Xu, Guang Yang, Zachary R Hunter, Steven P Treon
Waldenström macroglobulinaemia (WM) is a rare and incurable lymphoma. Comparative studies evaluating the efficacy of primary therapy in symptomatic WM patients have not been performed. In this study, we compared response and survival outcomes in WM patients who received primary therapy with cyclophosphamide-dexamethasone-rituximab (CDR), bortezomib-dexamethasone-rituximab (BDR) and bendamustine-rituximab (Benda-R), as well as maintenance rituximab following primary therapy. Analyses were adjusted for relevant clinical factors associated with response and survival...
February 22, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29465308/cll2-bxx-phase-ii-trials-sequential-targeted-treatment-for-eradication-of-minimal-residual-disease-in-chronic-lymphocytic-leukemia
#19
Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
AIM: Four Phase II trials (Clinical Trials numbers: NCT02345863, NCT02401503, NCT02445131 and NCT02689141) evaluate a different combination of targeted agents in an all-comer population of approximately 60 patients with chronic lymphocytic leukemia irrespective of prior treatment, physical fitness and genetic risk factors. Patients with a higher tumor load start with a debulking treatment with bendamustine. The subsequent induction and maintenance treatment with an anti-CD20 antibody (obinutuzumab or ofatumumab) and a targeted oral agent (ibrutinib, idelalisib or venetoclax) are continued until achievement of a complete response and minimal residual disease negativity...
February 21, 2018: Future Oncology
https://www.readbyqxmd.com/read/29452672/what-is-the-optimal-initial-management-of-the-older-mcl-patient
#20
REVIEW
Johanna C Kluin-Nelemans, Jeanette K Doorduijn
The current first line treatment of a patient with mantle cell lymphoma (MCL) is often considered as too toxic for elderly patients. The elderly, however, comprise the majority of the patients with MCL. The results of several recent studies have shown that the outcome of this patient group is not as dismal as in the past. Indeed, if patients are not considered frail, and can tolerate rituximab and moderate intensive chemotherapy such as R-CHOP followed by rituximab maintenance or R-bendamustine, a 4-year overall survival of >80% can be achieved...
March 2018: Best Practice & Research. Clinical Haematology
keyword
keyword
74879
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"